Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches

Siegel, 2017, Cancer statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 Xu, 2015, Androgen receptor splice variants dimerize to transactivate target genes, Cancer Res, 75, 3663, 10.1158/0008-5472.CAN-15-0381 Litwin, 2017, The diagnosis and treatment of prostate cancer: a review, JAMA, 317, 2532, 10.1001/jama.2017.7248 Watson, 2015, Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer, Nat Rev Cancer, 15, 701, 10.1038/nrc4016 Haag, 2005, Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells, J Steroid Biochem Mol Biol, 96, 251, 10.1016/j.jsbmb.2005.04.029 Zegarra-Moro, 2002, Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells, Cancer Res, 62, 1008 Balk, 2008, AR, the cell cycle, and prostate cancer, Nucl Recept Signal, 6, e001, 10.1621/nrs.06001 Knudsen, 1998, Elevated cyclins and cyclin-dependent kinase activity in the rhabdomyosarcoma cell line RD, Cancer Res, 58, 2042 Xu, 2006, Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins, Cancer Res, 66, 7783, 10.1158/0008-5472.CAN-05-4472 Ashikari, 2017, CLDN8, an androgen-regulated gene, promotes prostate cancer cell proliferation and migration, Cancer Sci, 108, 1386, 10.1111/cas.13269 Erzurumlu, 2017, Androgen mediated regulation of endoplasmic reticulum-associated degradation and its effects on prostate cancer, Sci Rep, 7, 40719, 10.1038/srep40719 Kim, 2017, The role of CREB3L4 in the proliferation of prostate cancer cells, Sci Rep, 7, 45300, 10.1038/srep45300 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Kron, 2017, TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer, Nat Genet, 49, 1336, 10.1038/ng.3930 Shih, 2015, Non-coding RNAs in Castration-resistant prostate cancer: regulation of androgen receptor signaling and cancer metabolism, Int J Mol Sci, 16, 28943, 10.3390/ijms161226138 Ribas, 2009, miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth, Cancer Res, 69, 7165, 10.1158/0008-5472.CAN-09-1448 Buscaglia, 2011, Apoptosis and the target genes of microRNA-21, Chin J Cancer, 30, 371, 10.5732/cjc.30.0371 Wan, 2016, Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy, Oncotarget, 7, 51284, 10.18632/oncotarget.9992 Ferreira, 2012, PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling, BMC Cancer, 12, 507, 10.1186/1471-2407-12-507 Salameh, 2015, PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3, Proc Natl Acad Sci U S A, 112, 8403, 10.1073/pnas.1507882112 Tomlins, 2016, Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment, Eur Urol, 70, 45, 10.1016/j.eururo.2015.04.039 Crea, 2014, Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer, Oncotarget, 5, 764, 10.18632/oncotarget.1769 Wang, 2009, Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer, Cell, 138, 245, 10.1016/j.cell.2009.04.056 Hu, 2012, Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer, Cancer Res, 72, 3457, 10.1158/0008-5472.CAN-11-3892 Wei, 2018, CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells, Mol Med Rep, 17, 2901 Ashikari, 2017, Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer, Oncogene, 36, 6272, 10.1038/onc.2017.225 Takayama, 2018, Association of USP10 with G3BP2 inhibits p53 signaling and contributes to poor outcome in prostate cancer, Mol Cancer Res, 10.1158/1541-7786.MCR-17-0471 Carter, 2016, IkappaBalpha mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor, BMC Cancer, 16, 141, 10.1186/s12885-016-2188-2 Lin, 2007, Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage, Cell Res, 17, 531, 10.1038/cr.2007.12 Kim, 2017, Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression, Expert Opin Ther Targets, 21, 911, 10.1080/14728222.2017.1369044 Lin, 2013, Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression, Biochem Biophys Res Commun, 430, 289, 10.1016/j.bbrc.2012.10.135 Anderson, 2016, The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism, Blood, 127, 3215, 10.1182/blood-2016-01-688796 Culig, 2014, Androgen receptor signaling in prostate cancer, Cancer Metastasis Rev, 33, 413, 10.1007/s10555-013-9474-0 Flaig, 2017, Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade, Oncotarget, 8, 56051, 10.18632/oncotarget.17359 Tennakoon, 2014, Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch, Oncogene, 33, 5251, 10.1038/onc.2013.463 Frigo, 2011, CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells, Cancer Res, 71, 528, 10.1158/0008-5472.CAN-10-2581 Massie, 2011, The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis, EMBO J, 30, 2719, 10.1038/emboj.2011.158 Kroiss, 2014, Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2, Oncogene, 34, 2846, 10.1038/onc.2014.222 Costello, 1997, Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells, J Biol Chem, 272, 28875, 10.1074/jbc.272.46.28875 Costello, 2006, The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots, Mol Cancer, 5, 17, 10.1186/1476-4598-5-17 White, 2018, GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling, Endocr Relat Cancer, 25, 453, 10.1530/ERC-17-0051 Audet-Walsh, 2017, Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer, Genes Dev, 31, 1228, 10.1101/gad.299958.117 Moon, 2011, Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells, Biochem J, 433, 225, 10.1042/BJ20101104 Tsouko, 2014, Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth, Oncogenesis, 3, e103, 10.1038/oncsis.2014.18 Itkonen, 2015, UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation, Oncogene, 34, 3744, 10.1038/onc.2014.307 Itkonen, 2013, O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells, Cancer Res, 73, 5277, 10.1158/0008-5472.CAN-13-0549 Itkonen, 2013, N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor, PLoS One, 8, e65016, 10.1371/journal.pone.0065016 Kaushik, 2016, Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer, Nat Commun, 7, 11612, 10.1038/ncomms11612 Wallitt, 2017, Clinical PET imaging in prostate cancer-erratum, Radiographics, 37, 2208, 10.1148/rg.2017174014 Butler, 2016, Androgen control of lipid metabolism in prostate cancer: novel insights and future applications, Endocr Relat Cancer, 23, R219, 10.1530/ERC-15-0556 Pinthus, 2007, Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer, Prostate, 67, 1330, 10.1002/pros.20609 Wu, 2014, Lipid metabolism in prostate cancer, Am J Clin Exp Urol, 2, 111 Rysman, 2010, De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation, Cancer Res, 70, 8117, 10.1158/0008-5472.CAN-09-3871 Deep, 2016, Aberrant lipid metabolism promotes prostate cancer: role in cell survival under hypoxia and extracellular vesicles biogenesis, Int J Mol Sci, 17, 1061, 10.3390/ijms17071061 Sadowski, 2014, The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer, Oncotarget, 5, 9362, 10.18632/oncotarget.2433 White, 2017, Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer, Mol Cancer Res, 15, 1017, 10.1158/1541-7786.MCR-16-0480 Wang, 2015, Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development, J Pathol, 236, 278, 10.1002/path.4518 Wang, 2011, Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression, Cancer Res, 71, 7525, 10.1158/0008-5472.CAN-11-1821 Blessing, 2017, Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression, Autophagy, 13, 506, 10.1080/15548627.2016.1268300 Shi, 2013, Androgens promote prostate cancer cell growth through induction of autophagy, Mol Endocrinol, 27, 280, 10.1210/me.2012-1260 Wang, 2013, Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development, J Natl Cancer Inst, 105, 1463, 10.1093/jnci/djt241 Schulte, 2016, 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel scaffold for inhibition of ASCT2-mediated glutamine transport, Bioorg Med Chem Lett, 26, 1044, 10.1016/j.bmcl.2015.12.031 Statz, 2017, mTOR inhibitors in castration-resistant prostate cancer: a systematic review, Target Oncol, 12, 47, 10.1007/s11523-016-0453-6 Levy, 2017, Targeting autophagy in cancer, Nat Rev Cancer, 17, 528, 10.1038/nrc.2017.53 Nowotarski, 2013, Polyamines and cancer: implications for chemotherapy and chemoprevention, Expert Rev Mol Med, 15, e3, 10.1017/erm.2013.3 Bai, 1998, Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells, J Androl, 19, 127 Shukla-Dave, 2016, Ornithine decarboxylase is sufficient for prostate tumorigenesis via androgen receptor signaling, Am J Pathol, 186, 3131, 10.1016/j.ajpath.2016.08.021 Devens, 2000, Polyamine depletion therapy in prostate cancer, Prostate Cancer Prostatic Dis, 3, 275, 10.1038/sj.pcan.4500420 Meyskens, 2014, Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine, Recent Results Cancer Res, 202, 115, 10.1007/978-3-642-45195-9_14 Schiewer, 2016, Linking DNA damage and hormone signaling pathways in cancer, Trends Endocrinol Metab, 27, 216, 10.1016/j.tem.2016.02.004 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Ta, 2014, The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer, Endocr Relat Cancer, 21, R395, 10.1530/ERC-14-0217 Ramakrishnan Geethakumari, 2017, PARP inhibitors in prostate cancer, Curr Treat Options Oncol, 18, 37, 10.1007/s11864-017-0480-2 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Karanika, 2015, DNA damage response and prostate cancer: defects, regulation and therapeutic implications, Oncogene, 34, 2815, 10.1038/onc.2014.238 Polkinghorn, 2013, Androgen receptor signaling regulates DNA repair in prostate cancers, Cancer Discov, 3, 1245, 10.1158/2159-8290.CD-13-0172 Goodwin, 2013, A hormone-DNA repair circuit governs the response to genotoxic insult, Cancer Discov, 3, 1254, 10.1158/2159-8290.CD-13-0108 Goodwin, 2015, DNA–PKcs-mediated transcriptional regulation drives prostate cancer progression and metastasis, Cancer Cell, 28, 97, 10.1016/j.ccell.2015.06.004 Al-Ubaidi, 2013, Castration therapy results in decreased Ku70 levels in prostate cancer, Clin Cancer Res, 19, 1547, 10.1158/1078-0432.CCR-12-2795 Karanika, 2017, Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6-ATR-Chk1 signaling, Cell Rep, 18, 1970, 10.1016/j.celrep.2017.01.072 Li, 2017, Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer, Sci Signal, 10 Russo, 2012, Angiogenesis in prostate cancer: onset, progression and imaging, BJU Int, 110, E794, 10.1111/j.1464-410X.2012.11444.x Eisermann, 2017, The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer, Cancers, 9, 32, 10.3390/cancers9040032 Eikesdal, 2009, Drug resistance associated with antiangiogenesis therapy, Semin Cancer Biol, 19, 310, 10.1016/j.semcancer.2009.05.006 Loges, 2010, Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates, Genes Cancer, 1, 12, 10.1177/1947601909356574 Abdollahi, 2010, Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy, Drug Resist Updat, 13, 16, 10.1016/j.drup.2009.12.001 Cotnoir-White, 2011, Evolution of the repertoire of nuclear receptor binding sites in genomes, Mol Cell Endocrinol, 334, 76, 10.1016/j.mce.2010.10.021 Xie, 2015, The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors, Int J Cancer, 136, E27, 10.1002/ijc.29147 Puhr, 2018, The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy, Clin Cancer Res, 24, 927, 10.1158/1078-0432.CCR-17-0989 Kroon, 2016, Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer, Endocr Relat Cancer, 23, 35, 10.1530/ERC-15-0343 Li, 2017, Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer, Elife, 6, e20183, 10.7554/eLife.20183 Kurmis, 2017, A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer, Cancer Res, 77, 2207, 10.1158/0008-5472.CAN-16-2503 Arora, 2013, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, Cell, 155, 1309, 10.1016/j.cell.2013.11.012 Swinnen, 1996, Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP, Endocrinology, 137, 4468, 10.1210/endo.137.10.8828509